These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 12681201)

  • 41. Treatment of diabetic nephropathy with angiotensin II receptor antagonist.
    Lewis EJ; Lewis JB
    Clin Exp Nephrol; 2003 Mar; 7(1):1-8. PubMed ID: 14586737
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Zofenopril or irbesartan plus hydrochlorothiazide in elderly patients with isolated systolic hypertension untreated or uncontrolled by previous treatment: a double-blind, randomized study.
    Modesti PA; Omboni S; Taddei S; Ghione S; Portaluppi F; Pozzilli P; Volpe M; Arca M; Calabrò P; Fulgheri PL; Bucci M; Berra S; Villani GQ; Vladoianu M; Popescu E; Velican VG; Pirvu O
    J Hypertens; 2016 Mar; 34(3):576-87; discussion 587. PubMed ID: 26703917
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Irbesartan: a review of its use in hypertension and in the management of diabetic nephropathy.
    Croom KF; Curran MP; Goa KL; Perry CM
    Drugs; 2004; 64(9):999-1028. PubMed ID: 15101793
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Efficacy and tolerability of combination therapy with valsartan plus hydrochlorothiazide compared with amlodipine monotherapy in hypertensive patients with other cardiovascular risk factors: the VAST study.
    Ruilope LM; Malacco E; Khder Y; Kandra A; Bönner G; Heintz D
    Clin Ther; 2005 May; 27(5):578-87. PubMed ID: 15978306
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A population-based European cohort study of persistence in newly diagnosed hypertensive patients.
    Hasford J; Mimran A; Simons WR
    J Hum Hypertens; 2002 Aug; 16(8):569-75. PubMed ID: 12149663
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Irbesartan lowers superoxide levels and increases nitric oxide bioavailability in blood vessels from spontaneously hypertensive stroke-prone rats.
    Brosnan MJ; Hamilton CA; Graham D; Lygate CA; Jardine E; Dominiczak AF
    J Hypertens; 2002 Feb; 20(2):281-6. PubMed ID: 11821713
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Polymorphisms in the angiotensinogen and angiotensin II type 1 receptor gene are related to change in left ventricular mass during antihypertensive treatment: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA) trial.
    Kurland L; Melhus H; Karlsson J; Kahan T; Malmqvist K; Ohman P; Nyström F; Hägg A; Lind L
    J Hypertens; 2002 Apr; 20(4):657-63. PubMed ID: 11910301
    [TBL] [Abstract][Full Text] [Related]  

  • 48. I-ADD study: assessment of efficacy and safety profile of irbesartan/amlodipine fixed-dose combination therapy compared with irbesartan monotherapy in hypertensive patients uncontrolled with irbesartan 150 mg monotherapy: a multicenter, phase III, prospective, randomized, open-label with blinded-end point evaluation study.
    Bobrie G;
    Clin Ther; 2012 Aug; 34(8):1720-34.e3. PubMed ID: 22853847
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Matrix study of irbesartan with hydrochlorothiazide in mild-to-moderate hypertension.
    Kochar M; Guthrie R; Triscari J; Kassler-Taub K; Reeves RA
    Am J Hypertens; 1999 Aug; 12(8 Pt 1):797-805. PubMed ID: 10480473
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Effectiveness and safety of the angiotensin II antagonist irbesartan in children with chronic kidney diseases.
    Franscini LM; Von Vigier RO; Pfister R; Casaulta-Aebischer C; Fossali E; Bianchetti MG
    Am J Hypertens; 2002 Dec; 15(12):1057-63. PubMed ID: 12460701
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Comparative efficacy of two angiotensin II receptor antagonists, irbesartan and losartan in mild-to-moderate hypertension. Irbesartan/Losartan Study Investigators.
    Kassler-Taub K; Littlejohn T; Elliott W; Ruddy T; Adler E
    Am J Hypertens; 1998 Apr; 11(4 Pt 1):445-53. PubMed ID: 9607383
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Reasons for not intensifying antihypertensive treatment (RIAT): a primary care antihypertensive intervention study.
    Ferrari P; Hess L; Pechere-Bertschi A; Muggli F; Burnier M
    J Hypertens; 2004 Jun; 22(6):1221-9. PubMed ID: 15167458
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A home blood pressure monitoring study comparing the antihypertensive efficacy of two angiotensin II receptor antagonist fixed combinations.
    Bobrie G; Delonca J; Moulin C; Giacomino A; Postel-Vinay N; Asmar R;
    Am J Hypertens; 2005 Nov; 18(11):1482-8. PubMed ID: 16280286
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes.
    Lewis EJ; Hunsicker LG; Clarke WR; Berl T; Pohl MA; Lewis JB; Ritz E; Atkins RC; Rohde R; Raz I;
    N Engl J Med; 2001 Sep; 345(12):851-60. PubMed ID: 11565517
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Randomized, double-blind comparison of irbesartan and enalapril for treatment of mild to moderate hypertension.
    Chiou KR; Chen CH; Ding PY; Chen YT; Ting CT; Huang JL; Chiang AH; Liu CP; Tseng CJ; Chao CT; Chang MS
    Zhonghua Yi Xue Za Zhi (Taipei); 2000 May; 63(5):368-76. PubMed ID: 10862446
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Treatment with irbesartan or atenolol improves endothelial function in essential hypertension.
    von zur Mühlen B; Kahan T; Hägg A; Millgård J; Lind L
    J Hypertens; 2001 Oct; 19(10):1813-8. PubMed ID: 11593101
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes.
    Parving HH; Lehnert H; Bröchner-Mortensen J; Gomis R; Andersen S; Arner P;
    N Engl J Med; 2001 Sep; 345(12):870-8. PubMed ID: 11565519
    [TBL] [Abstract][Full Text] [Related]  

  • 58. AT1-receptor antagonism in hypertension: what has been learned with irbesartan?
    Waeber B; Burnier M
    Expert Rev Cardiovasc Ther; 2003 May; 1(1):23-33. PubMed ID: 15030294
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Dose-related efficacy of irbesartan in patients, with mild-to-moderate essential hypertension.
    Grimbert P; Grenier O; Thuillez C;
    Therapie; 2005; 60(6):577-82. PubMed ID: 16555496
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [The control rate of irbesartan/hydrochlorothiazide combination regimen in the treatment of Chinese patients with mild to moderate hypertension].
    Sun NL; Jing S; Chen J
    Zhonghua Xin Xue Guan Bing Za Zhi; 2005 Jul; 33(7):618-21. PubMed ID: 16080809
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.